ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hansoh Pharmaceutical Group and Regeneron Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hansoh Pharmaceutical GroupRegeneron Pharmaceuticals
studies on the registry190414
open to participants now11784
phase 3 studies under way2138
reach primary completion within a year2730
programswith a study of their own in two years4443

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHansoh Pharmaceutical GroupRegeneron Pharmaceuticals
Phase 1

Hansoh Pharmaceutical Group: 21 of its 44 programs at phase 1

  1. HS-20122phase 1
  2. HS-20136-2phase 1
  3. PARP1 Inhibitor HS-10502phase 1
  4. Alveltamigphase 1
  5. apatinibphase 1

and 16 more — sign in to see them all

48%

Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20934phase 1

and 3 more — sign in to see them all

19%
Phase 2

Hansoh Pharmaceutical Group: 9 of its 44 programs at phase 2

  1. HS-20118phase 2
  2. HIF-2alpha Inhibitor HS-10516phase 2
  3. HS-10390phase 2
  4. HS-10542phase 2
  5. RET Inhibitor HS-10365phase 2

and 4 more — sign in to see them all

20%

Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

37%
Phase 3

Hansoh Pharmaceutical Group: 13 of its 44 programs at phase 3

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. HS-10506phase 3
  4. aumolertinibphase 3
  5. mocertatug rezetecanphase 3

and 8 more — sign in to see them all

30%

Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

35%
Approved, new studies

Hansoh Pharmaceutical Group: 1 of its 44 programs at approved, new studies

  1. tenofovir amibufenamideapproved, new study
2%

Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hansoh Pharmaceutical Group16 readouts · 2 phase 3·

Hansoh Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion

  1. HS-20118phase 2 · Dec 25 · NCT07896915
  2. risvutatug rezetecanphase 3 · Dec 30 · NCT06699576
  3. HS-10504phase 3 · Dec 31 · NCT06461156
  4. HS-20110phase 1 · Dec 31 · NCT06892379
  5. HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.phase 1 · Dec 31 · NCT06892379

and 1 more — sign in to see them all

Hansoh Pharmaceutical Group, Jan ’27: 2 programs whose next study reaches primary completion

  1. HS-20152phase 1 · Jan 1 · NCT07503015
  2. HS-10522phase 1 · Jan 20 · NCT07609875

Hansoh Pharmaceutical Group, Feb ’27: 1 program whose next study reaches primary completion

  1. Embibatinibphase 3 · Feb 0 · NCT07933224

Hansoh Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. HS-20137phase 3 · Mar 1 · NCT07879885
  2. mocertatug rezetecanphase 3 · Mar 7 · NCT06855069
  3. olatorepatidephase 3 · Mar 30 · NCT07156500
·

Hansoh Pharmaceutical Group, May ’27: 2 programs whose next study reaches primary completion

  1. HS-10542phase 2 · May 30 · NCT07470762
  2. HS-10582phase 1 · May 30 · NCT07777003
·

Hansoh Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion

  1. HIF-2alpha Inhibitor HS-10516phase 2 · Jul 10 · NCT07097935

Hansoh Pharmaceutical Group, Aug ’27: 1 program whose next study reaches primary completion

  1. RET Inhibitor HS-10365phase 2 · Aug 31 · NCT06147570
··
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hansoh Pharmaceutical Group

New programs 1

  • HS-20197phase 1 · first study · Sep 10

Reached a new phase 2

Study stopped 0

None

Primary completion later 0

None

Regeneron Pharmaceuticals

New programs 5

  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 19 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionHansoh Pharmaceutical GroupRegeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lungboth · compare here

Hansoh Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. risvutatug rezetecanphase 3
  2. HS-10504phase 3
  3. aumolertinibphase 3
  4. HS-20117phase 3
  5. dalmelitinibphase 3

and 5 more — sign in to see them all

Their studies: Hansoh Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3
  3. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsboth · compare here

Hansoh Pharmaceutical Group in Neoplasms: 5 programs

  1. risvutatug rezetecanphase 3
  2. mocertatug rezetecanphase 3
  3. dalmelitinibphase 3
  4. adebrelimabphase 2
  5. apatinibphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Neoplasms in search

Regeneron Pharmaceuticals in Neoplasms: 2 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Neoplasms in search

Obesityboth · compare here

Hansoh Pharmaceutical Group in Obesity: 2 programs

  1. olatorepatidephase 3
  2. HS-20136-2phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Obesity in search

Regeneron Pharmaceuticals in Obesity: 5 programs

  1. ALN-CIDEBphase 3
  2. olatorepatidephase 3
  3. mibavademabphase 3
  4. garetosmabphase 3
  5. REGN20934phase 1

Their studies: Regeneron Pharmaceuticals’ studies of Obesity in search

Ovarian Neoplasmsboth · compare here

Hansoh Pharmaceutical Group in Ovarian Neoplasms: 4 programs

  1. mocertatug rezetecanphase 3
  2. PARP1 Inhibitor HS-10502phase 1
  3. apatinibphase 1
  4. Platinum Compoundsphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Ovarian Neoplasms in search

Regeneron Pharmaceuticals in Ovarian Neoplasms: 1 program

  1. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Ovarian Neoplasms in search

Prostatic Neoplasmsboth · compare here

Hansoh Pharmaceutical Group in Prostatic Neoplasms: 3 programs

  1. risvutatug rezetecanphase 3
  2. Alveltamigphase 1
  3. HRS-5041phase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Prostatic Neoplasms in search

Regeneron Pharmaceuticals in Prostatic Neoplasms: 2 programs

  1. olsutamigphase 2
  2. REGN21353phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Prostatic Neoplasms in search

Hemoglobinuria, Paroxysmalboth · compare here

Hansoh Pharmaceutical Group in Hemoglobinuria, Paroxysmal: 1 program

  1. HS-10542phase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Hemoglobinuria, Paroxysmal in search

Regeneron Pharmaceuticals in Hemoglobinuria, Paroxysmal: 3 programs

  1. cemdisiranphase 3
  2. ALN-CFBphase 2
  3. pozelimabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Hemoglobinuria, Paroxysmal in search

Carcinoma, Renal Cellboth · compare here

Hansoh Pharmaceutical Group in Carcinoma, Renal Cell: 1 program

  1. HIF-2alpha Inhibitor HS-10516phase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Carcinoma, Renal Cell in search

Regeneron Pharmaceuticals in Carcinoma, Renal Cell: 2 programs

  1. olsutamigphase 2
  2. Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Renal Cell in search

Dyslipidemiasboth · compare here

Hansoh Pharmaceutical Group in Dyslipidemias: 2 programs

  1. HS-10582phase 1
  2. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Dyslipidemias in search

Regeneron Pharmaceuticals in Dyslipidemias: 1 program

  1. ALN-APOC3phase 1

Their studies: Regeneron Pharmaceuticals’ studies of Dyslipidemias in search

Glomerulonephritis, IGAboth · compare here

Hansoh Pharmaceutical Group in Glomerulonephritis, IGA: 2 programs

  1. HS-10390phase 2
  2. HS-10542phase 2

Their studies: Hansoh Pharmaceutical Group’s studies of Glomerulonephritis, IGA in search

Regeneron Pharmaceuticals in Glomerulonephritis, IGA: 1 program

  1. cemdisiranphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Glomerulonephritis, IGA in search

Hypertensionboth · compare here

Hansoh Pharmaceutical Group in Hypertension: 2 programs

  1. HS-10522phase 1
  2. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Hypertension in search

Regeneron Pharmaceuticals in Hypertension: 1 program

  1. vixticibartphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Hypertension in search

Coronary Artery Diseaseboth · compare here

Hansoh Pharmaceutical Group in Coronary Artery Disease: 1 program

  1. rosuvastatinphase 1

Their studies: Hansoh Pharmaceutical Group’s studies of Coronary Artery Disease in search

Regeneron Pharmaceuticals in Coronary Artery Disease: 1 program

  1. alirocumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Coronary Artery Disease in search

Diabetes Mellitus, Type 2both · compare here

Hansoh Pharmaceutical Group in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Hansoh Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Show all 19

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetHansoh Pharmaceutical GroupRegeneron Pharmaceuticals
CD3EAlveltamigrulelinvoseltamabrule, odronextamabrule, olsutamigrule, REGN17372rule, REGN9220rule, vonsetamigrule
GIPRolatorepatideolatorepatide
GLP1Rolatorepatideolatorepatide
A target, or a pathogen for a vaccine, known for: Hansoh Pharmaceutical Group 29 of 44 · Regeneron Pharmaceuticals 17 of 43 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.